Johnson SD

Methods: We did a retrospective review of 55 patients with prostate cancer treated using external beam radiation therapy VMAT between 2013 through 2017.

Results: Sixteen were adjuvant/salvage therapy to the prostate fossa (PF) after a prostatectomy while 39 had primary radiation therapy for intact prostate cancer. The dose volume histogram (DVH) institutional bladder constraints were v65 200 cc, 55% when > 150 cc and there were no incidences of hematuria when the PTV was < 150 cc.

Conclusions: (1) Overall incidence of hematuria with VMAT treatment to the prostate was 10/55(18%); (2) Higher bladder DVH v65 volumes correlated with higher incidence of hematuria; (3) Higher PTV in PF group correlated with higher incidence of hematuria with the greatest risk occurring when the PTV was greater than 200 cc. This is due to more bladder in the treatment field; (4) Careful patient selection should be made for surgery to avoid post-surgery radiation therapy; (5) When treating PF keep the PTV volume under 150 cc; and (6) This finding should be studied with larger number of patients.

Methods: We did a retrospective review of 55 patients with prostate cancer treated using external beam radiation therapy VMAT between 2013 through 2017.

Results: Sixteen were adjuvant/salvage therapy to the prostate fossa (PF) after a prostatectomy while 39 had primary radiation therapy for intact prostate cancer. The dose volume histogram (DVH) institutional bladder constraints were v65 200 cc, 55% when > 150 cc and there were no incidences of hematuria when the PTV was < 150 cc.

Conclusions: (1) Overall incidence of hematuria with VMAT treatment to the prostate was 10/55(18%); (2) Higher bladder DVH v65 volumes correlated with higher incidence of hematuria; (3) Higher PTV in PF group correlated with higher incidence of hematuria with the greatest risk occurring when the PTV was greater than 200 cc. This is due to more bladder in the treatment field; (4) Careful patient selection should be made for surgery to avoid post-surgery radiation therapy; (5) When treating PF keep the PTV volume under 150 cc; and (6) This finding should be studied with larger number of patients.

Methods: We did a retrospective review of 55 patients with prostate cancer treated using external beam radiation therapy VMAT between 2013 through 2017.

Results: Sixteen were adjuvant/salvage therapy to the prostate fossa (PF) after a prostatectomy while 39 had primary radiation therapy for intact prostate cancer. The dose volume histogram (DVH) institutional bladder constraints were v65 200 cc, 55% when > 150 cc and there were no incidences of hematuria when the PTV was < 150 cc.

Conclusions: (1) Overall incidence of hematuria with VMAT treatment to the prostate was 10/55(18%); (2) Higher bladder DVH v65 volumes correlated with higher incidence of hematuria; (3) Higher PTV in PF group correlated with higher incidence of hematuria with the greatest risk occurring when the PTV was greater than 200 cc. This is due to more bladder in the treatment field; (4) Careful patient selection should be made for surgery to avoid post-surgery radiation therapy; (5) When treating PF keep the PTV volume under 150 cc; and (6) This finding should be studied with larger number of patients.

Background: Radiation therapy (RT) for lung cancer is a standard of care. Radiation exposure to normal lung tissue can cause loss of function due to pneumonitis and fibrosis. We evaluated subjectively and objectively with pulmonary function tests (PFT) for toxicity following RT.

Objective: The purpose of our retrospective study was to correlate post radiation PFT changes and symptoms.

Methods: We studied retrospectively 18 patients with lung cancer treated at the Jackson VAMC between 2014 and 2016. All patients had pretreatment and posttreatment PFTs. Symptoms of dyspnea were graded using the Common Terminology Criteria for Adverse Events (CTCAE).

Results: Sixteen received SBRT; (15 with 50 Gy in 5 fractions; one 48 Gy in 4 fractions); one 60 Gy in 6 weeks and one 45 Gy in 30 bid fractions. Sites of treatment included 13 (72%) upper lobe, 2 (11%) right middle lobe and 3 (17%) lower lobe. The median drop in FEV1 posttreatment was 0.15. While 8 (44%) patients had grade I/II dyspnea prior to treatment, 14 (78%) patients had the same after treatment. Only 1 patient who received both SBRT to LUL and Conventional XRT to the mediastinum developed grade II dyspnea. His FEV1 dropped 37% or 0.37 from baseline. Symptomatically 11 (61%) had no increased dyspnea with a median FEV1 drop of 3% or 0.06 from baseline; while 7 (39%) patients had worsening of dyspnea after treatment with a median drop of 0.23 (11%) from baseline in FEV1. Patients treated in the middle and lower lobes had a median FEV1 drop of 0.43 from baseline There was no significant median change (+0.04) when treating the upper lobe. 38% of patients who had an upper lobe treated complained of worsening dyspnea, while 66% of patients with lower lobe treated reported worsening dyspnea.

Conclusions: After definitive XRT, 39% of patients had worsening in symptoms with a median drop of 11% in the FEV1, compared to only a 3% drop in FEV1 in patients who did not report a worsening of symptoms. Patients with lower lobe tumors had greater PFT changes with worsening dyspnea.

Background: Radiation therapy (RT) for lung cancer is a standard of care. Radiation exposure to normal lung tissue can cause loss of function due to pneumonitis and fibrosis. We evaluated subjectively and objectively with pulmonary function tests (PFT) for toxicity following RT.

Objective: The purpose of our retrospective study was to correlate post radiation PFT changes and symptoms.

Methods: We studied retrospectively 18 patients with lung cancer treated at the Jackson VAMC between 2014 and 2016. All patients had pretreatment and posttreatment PFTs. Symptoms of dyspnea were graded using the Common Terminology Criteria for Adverse Events (CTCAE).

Results: Sixteen received SBRT; (15 with 50 Gy in 5 fractions; one 48 Gy in 4 fractions); one 60 Gy in 6 weeks and one 45 Gy in 30 bid fractions. Sites of treatment included 13 (72%) upper lobe, 2 (11%) right middle lobe and 3 (17%) lower lobe. The median drop in FEV1 posttreatment was 0.15. While 8 (44%) patients had grade I/II dyspnea prior to treatment, 14 (78%) patients had the same after treatment. Only 1 patient who received both SBRT to LUL and Conventional XRT to the mediastinum developed grade II dyspnea. His FEV1 dropped 37% or 0.37 from baseline. Symptomatically 11 (61%) had no increased dyspnea with a median FEV1 drop of 3% or 0.06 from baseline; while 7 (39%) patients had worsening of dyspnea after treatment with a median drop of 0.23 (11%) from baseline in FEV1. Patients treated in the middle and lower lobes had a median FEV1 drop of 0.43 from baseline There was no significant median change (+0.04) when treating the upper lobe. 38% of patients who had an upper lobe treated complained of worsening dyspnea, while 66% of patients with lower lobe treated reported worsening dyspnea.

Conclusions: After definitive XRT, 39% of patients had worsening in symptoms with a median drop of 11% in the FEV1, compared to only a 3% drop in FEV1 in patients who did not report a worsening of symptoms. Patients with lower lobe tumors had greater PFT changes with worsening dyspnea.

Background: Radiation therapy (RT) for lung cancer is a standard of care. Radiation exposure to normal lung tissue can cause loss of function due to pneumonitis and fibrosis. We evaluated subjectively and objectively with pulmonary function tests (PFT) for toxicity following RT.

Objective: The purpose of our retrospective study was to correlate post radiation PFT changes and symptoms.

Methods: We studied retrospectively 18 patients with lung cancer treated at the Jackson VAMC between 2014 and 2016. All patients had pretreatment and posttreatment PFTs. Symptoms of dyspnea were graded using the Common Terminology Criteria for Adverse Events (CTCAE).

Results: Sixteen received SBRT; (15 with 50 Gy in 5 fractions; one 48 Gy in 4 fractions); one 60 Gy in 6 weeks and one 45 Gy in 30 bid fractions. Sites of treatment included 13 (72%) upper lobe, 2 (11%) right middle lobe and 3 (17%) lower lobe. The median drop in FEV1 posttreatment was 0.15. While 8 (44%) patients had grade I/II dyspnea prior to treatment, 14 (78%) patients had the same after treatment. Only 1 patient who received both SBRT to LUL and Conventional XRT to the mediastinum developed grade II dyspnea. His FEV1 dropped 37% or 0.37 from baseline. Symptomatically 11 (61%) had no increased dyspnea with a median FEV1 drop of 3% or 0.06 from baseline; while 7 (39%) patients had worsening of dyspnea after treatment with a median drop of 0.23 (11%) from baseline in FEV1. Patients treated in the middle and lower lobes had a median FEV1 drop of 0.43 from baseline There was no significant median change (+0.04) when treating the upper lobe. 38% of patients who had an upper lobe treated complained of worsening dyspnea, while 66% of patients with lower lobe treated reported worsening dyspnea.

Conclusions: After definitive XRT, 39% of patients had worsening in symptoms with a median drop of 11% in the FEV1, compared to only a 3% drop in FEV1 in patients who did not report a worsening of symptoms. Patients with lower lobe tumors had greater PFT changes with worsening dyspnea.